

Appl. No. : 09/619,059
Filed : July 18, 2000

Sub E1
7. (New) The composition of claim 2, further comprising a pharmaceutically acceptable preservative.

8. (New) The composition of claim 7, wherein the preservative is selected from the group consisting of benzyl alcohol, phenol, m-cresol, methylparaben, and propylparaben.

9. (New) The composition of claim 7, wherein the preservative is benzyl alcohol.

Sub E2
10. (New) The composition of claim 2, wherein the benzyl alcohol concentration is from 0.1 to 2.0%.

Sub E1
11. (New) The composition of claim 2, further comprising a pharmaceutically acceptable surfactant.

12. (New) The composition of claim 2, further comprising a physiologically acceptable concentration of sodium chloride.

Sub E3
13. (New) The composition according to claim 2, wherein the nerve growth factor has a concentration of at least about 0.1 mg/ml and said acetate ion has a concentration of 10 mM to 50 mM.

14. (New) The composition according to claim 2, wherein said nerve growth factor has a concentration of 0.1 to about 2.0 mg/ml and said acetate ion has a concentration of 10 mM to 50 mM.

15. (New) The composition of claim 2, wherein the NGF concentration is 0.1 mg/ml, the sodium acetate concentration is 20 mM, the pH is 5.5, the sodium chloride concentration is 136 mM, and benzyl alcohol is 0.9% (v/v).

16. (New) The composition of claim 2, wherein the NGF concentration is 2.0 mg/ml, the sodium acetate concentration is 10 mM, the pH is 5.5, and the sodium chloride concentration is 142 mM.

Sub E1
17. (New) The composition of claim 2, wherein the nerve growth factor is 118 amino acid NGF.

Sub E3
18. (New) A composition produced by the process comprising formulating nerve growth factor and a pharmaceutically acceptable acetate-containing buffer.

A' Sub E1
19. (New) The composition of claim 18 wherein the composition is formulated with 0.1 mg/ml, 20 mM sodium acetate, 136 mM sodium chloride, 0.9% (v/v) benzyl alcohol, at pH of 5.5.

Appl. No. : 09/619,059
Filed : July 18, 2000

sub E1) 20. (New) The composition of claim 18, wherein the nerve growth factor 118/118 rhNGF.

A1 sub E1) 21. (New) The composition of claim 18, wherein the nerve growth factor is secreted from Chinese hamster ovary cells.

CONCLUSION

Applicants wish to thank the Examiner for her agreeing to consider this preliminary amendment prior to commencement of substantive examination of this case.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 23 July 2001

By: 

James J. Mullen III, Ph.D.
Registration No. 44,957
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(619) 687-8603

S:\DOCS\UJM\UJM-6371.DOC
072401